- Details
- In conversation with Alicia Morgans, Philip Koo discusses data from a phase II trial that randomized patients to receive radium-223 and sipuleucel-T or sipuleucel-T alone. Dr. Koo explains that patients who received the combination saw a better PSA response, providing evidence for the continued exploration of the combination of radiation and immunotherapy. Biographies: Phillip J. Koo, MD , FACS Di...
|
- Details
- Matthew Smith shares his thoughts on the importance of bone health in the prostate cancer patient population. Osteoporotic or fragility fractures are common due to the age of the patient and long-term androgen deprivation therapy. Fractures have a great impact on patient mortality, mobility, independence, and overall quality of life. Dr. Smith addresses questions regarding bone density measurement...
|
- Details
- Neal Shore joins Alicia Morgans in a discussion on the optimal timing to use radium-223 (Xofigo®) in metastatic castration-resistant prostate cancer (mCRPC). Together they discuss the window of opportunity for administering radium-223 and what we have learned from the ALSYMPCA and ERA-223 trials. Dr. Shore recaps how radium-223 is being used prior to docetaxel and how it is being layered with an a...
|
- Details
- Neal Shore and Bertrand Tombal discuss the importance of bone health agents, particularly in patients receiving castrate-resistant prostate cancer agents. Highlights of their conversation include the use of antiresorptive therapy to reduce the risk of skeletal-related events in men with bone mCRPC and decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial. Bi...
|
- Details
- Chris Parker presents on the utilization of antiresorptive therapy to reduce skeletal-related events (SRE) risk in men with bone metastatic castration-resistant prostate cancer (mCRPC) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Parker's presentation was part of a debate featured during the Bone and Bone Metastases Session. He summarized the evidence base in 2002 after t...
|
- Details
- Evan Yu and Alicia Morgans share in a discussion on where we are in understanding treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) and sequencing treatments after progression from nmCPRC to mCRPC. The conversation includes selecting and evaluating patients with mCRPC and how treatments are selected for these patients. Dr. Yu discusses the opportunities to individualize tr...
|
- Details
- Dan George concentrated on the patient experience in the treatment of metastatic castration-resistant prostate cancer (mCRPC). He described a typical treatment timeline where a new patient presents with elevated PSA is initially treated with androgen deprivation therapy (ADP) to reduce testosterone feeding tumor growth. While the patient may initially respond with a reduced PSA, it is most common...
|
- Details
- Charles Ryan, MD, and Fred Saad, MD have a clinical discussion on the full spectrum of castration-resistant prostate cancer (CRPC) from inception in both symptomatic vs asymptomatic patients from the evolution of abiraterone acetate and enzalutamide to the time point of integrating therapies earlier into CRPC. Dr. Saad discusses the development of prostate cancer and the optimal way for clinicians...
|
- Details
- Neal Shore and Oliver Sartor discuss the role of both alpha and beta radiopharmaceuticals that are on the horizon for treatment of bone metastases in prostate cancer. Dr. Sartor reviews the compelling data for the use radium-223 with respect to the improvement seen in overall survival along with additional alpha targeted agents that are on the horizon. He also discusses the role of the beta agents...
|
- Details
- Daniel George is joined by a multi-specialty group of experts to discuss the latest research on CRPC with bone metastases. The conversation details the mechanism of action of Radium-223 in prostate cancer, a review of the ALSYMPCA trial and the impact of the ERA-223 trial. Biographies: Daniel George, MD is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke Uni...
|
